


CLAIMS

1. Use of methoxymorpholino doxorubicin (MMDX) of formula



5 in the preparation of a medicament formulated for
intrahepatic administration in the treatment of a human
liver tumour.

10 2. Use according to claim 1. wherein the liver tumor is a
tumor primarily confined to the liver.

Sub
AI 3. Use according to claim 2. wherein the tumor primarily
confined to the liver is a hepatocellular carcinoma (HCC)
or a cholangiocarcinoma.

15 4. Use according to claim 1. wherein the tumor is a liver
metastasis.

20 5. Use according to any one of the preceding claims wherein
the intrahepatic administration of MMDX is via the hepatic
artery.

6. Use according to any one of the preceeding claims wherein MMDX is administered as an infusion of from about 15 minutes to about 30 minutes every 4 weeks.

5 7. Use according to anyone of claims 1. to 6. wherein MMDX is administered as a 5-10 minute bolus every 8 weeks.

Sub A1
10 8. Use according to any one of the preceeding claims wherein MMDX is administered with an agent which remains selectively in a liver tumor after its injection through the hepatic artery.

15 9. Use according to claim 8. wherein the agent is iodized oil.

10 10. Use according to anyone of the preceeding claims wherein MMDX is administered in a dose ranging from about 100 mcg/m² to about 1000 mcg/m².

20 11. Use according to claim 10. wherein MMDX is administered in a dose ranging form about 100 mcg/m² to about 800 mcg/m².

25 12. Use according to claim 11. wherein the dose is 200 mcg/m².

30 13. A pharmaceutical composition which comprises as an active principle MMDX and a pharmaceutically acceptable agent which remains selectively in a liver tumor after its injection through the hepatic artery.

14. A pharmaceutical composition according to claim 13.
wherein the agent is iodized oil.

5 15. Use of a pharmaceutical composition according to claim
13. or 14. for the treatment of a liver tumor.

sub
A2
10 16. Use of a pharmaceutical composition which comprises as an
active principle MMDX and a pharmaceutically acceptable
agent which remains selectively in a liver tumor after
its injection through the hepatic artery, for the
preparation of a medicament formulated for intrahepatic
administration in the treatment of a human liver tumor.

15 17. Use according to claim 16 wherein the agent is iodized
oil.

18. A method of treating a human liver tumor which comprises
the intrahepatic administration of a therapeutically
effective amount of MMDX to a patient in need thereof.

20 19. A method for reducing MMDX systemic exposure of a patient
suffering from a liver cancer which comprises the
intrahepatic administration of a therapeutically
effective amount of MMDX to said patient.